贝伐珠单抗靶向治疗卵巢癌患者对肿瘤标志物的影响

Effect of Bevacizumab Targeted Therapy on Tumor Markers in Patients With Ovarian Cancer

目的探讨贝伐珠单抗靶向治疗卵巢癌对肿瘤标志物的影响。方法选取2019年1月—2021年12月福建医科大学附属福州市第一医院收治的80例卵巢癌患者,根据不同治疗药物进行分组,分别纳入单独行化疗的化疗组和行贝伐珠单抗靶向治疗的靶向组,每组40例。测评2组治疗前后肿瘤标志物蛋白芯片中糖链抗原125(glycoantigens in protein chips-125,CA-125)、人附睾蛋白4(Human epididymal protein 4,HE4)水平及血管内皮生长因子(vascular endothelial growth factor,VEGF)水平,治疗后客观缓解率、疾病控制率、免疫指标、癌症患者生命质量测定量表(quality of life scale for cancer patients,FACT-G)和抑郁自评量表(self-rating depression scale,SDS)、焦虑自评量表(self-rating anxiety scale,SAS)评分。结果治疗后,靶向组治疗客观缓解率为65.00%,疾病控制率为87.50%,高于化疗组的42.50%、70.00%(P<0.05);靶向组CA-125、HE4、VEGF指标低于化疗组,CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于化疗组,FACT-G评分高于化疗组,而SDS、SAS评分低于化疗组,差异有统计学意义(P<0.05)。结论贝伐珠单抗靶向治疗卵巢癌患者可抑制肿瘤新生血管形成和生长,增强治疗效果,改善患者的心理情绪和生活质量。

Objective To investigate the effect of bevacizumab targeted therapy on tumor markers of ovarian cancer.Methods A total of 80 patients with ovarian cancer admitted to Fuzhou First Hospital Affiliated to Fujian Medical University from January 2019 to December 2021 were selected and divided into groups according to different therapeutic drugs,and were included in the chemotherapy group receiving chemotherapy alone and the targeted group receiving bevacizumab targeted therapy,40 cases in each group.Glycoantigens in protein chips-125(CA-125)and human epididymal protein 4(HE4)level,vascular endothelial growth factor(VEGF)level,objective response rate,disease control rate,immune markers,and quality of life scale for cancer patients(FACT-G),self-rating depression scale(SDS),and self-rating anxiety scale(SAS)were measured before and after treatment in 2 groups.Results After treatment,the objective remission rate and disease control rate of the targeted group were 65.00%and 87.50%,which were higher than 42.50%and 70.00%in the chemotherapy group(P<0.05).The indexes of CA-125,HE4 and VEGF in the targeted group were lower than those in the chemotherapy group;CD3^(+),^(+)CD4 and CD4^(+)/CD8^(+)were higher than those in the chemotherapy group,FACT-G scores were higher than those in the chemotherapy group,SDS and SAS scores were lower than those in the chemotherapy group,with statistical significance(P<0.05).Conclusion Bevacizumab can inhibit the formation and growth of tumor neovascularization,enhance the therapeutic effect,and improve the psychological emotion and quality of life of patients with ovarian cancer.